Ozempic and Wegovy in Early Pregnancy
Quick Facts
Is it safe to take Ozempic or Wegovy in early pregnancy?
GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy), are widely prescribed for type 2 diabetes and obesity. Many users are women of reproductive age, and some become pregnant unexpectedly, partly because weight loss can improve fertility. Randomized trials generally exclude pregnant women, so most safety evidence comes from registries, insurance claims, and electronic health records.
A study of more than 750,000 pregnancies compared outcomes in people exposed to these drugs early in pregnancy with those not exposed. According to ScienceDaily's summary, early exposure was not linked to increased pregnancy complications when the drugs were used for weight loss. The summary also notes an association in another context, which readers should check against the full paper. Observational data of this kind can be affected by differences between the people who take a drug and those who do not, such as body weight, diabetes status, and other health conditions.
Why does the reason for taking the drug matter?
Pregnancy outcomes differ with the underlying condition. Obesity is associated with higher risks of gestational diabetes, hypertensive disorders, and cesarean delivery, and pre-existing diabetes carries additional risks. When researchers compare drug-exposed and unexposed groups, they must separate the effect of the medicine from the effect of the condition it treats. That is why findings can differ between people taking these drugs for weight loss and those taking them for diabetes.
For clinicians, the practical message is about planning. The US prescribing information for Wegovy advises discontinuing the drug when pregnancy is recognized, and many clinicians recommend stopping it before a planned conception. Women who become pregnant while taking a GLP-1 drug should talk to their obstetric provider promptly rather than stopping abruptly on their own, since blood sugar control may matter for those with diabetes. Larger, longer studies that track infant outcomes will be needed to settle remaining questions.
Frequently Asked Questions
Prescribing information advises discontinuing weight-loss formulations when pregnancy is recognized. Contact your doctor promptly to plan next steps, especially if you also have diabetes.
No. Observational studies can show associations but cannot prove safety, and they may be affected by differences between treated and untreated groups.
Many clinicians advise discussing timing with a provider and stopping the drug before conception. The right plan depends on individual health and the reason for treatment.
References
- ScienceDaily. Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy. November 2026.
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information.
- World Health Organization. Obesity and overweight fact sheet.